<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468493</url>
  </required_header>
  <id_info>
    <org_study_id>GGH-1-1</org_study_id>
    <nct_id>NCT01468493</nct_id>
  </id_info>
  <brief_title>A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients</brief_title>
  <acronym>SuparSDRF</acronym>
  <official_title>A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the improved responsiveness to treatment
      achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be
      explained by CsA's inhibitory action on the circulating suPAR expression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum suPAR level when proteinuria reduction &gt;=50% or complete remission</measure>
    <time_frame>6 months after steriod alone or CsA plus steriod treatment</time_frame>
    <description>serum suPAR level when proteinuria reduction of &gt;=50% or complete remission occurs within &lt;=6 months of steroid alone or CsA plus steroid treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum suPAR level after 6 months of steroid or CsA treatment without remission</measure>
    <time_frame>6 months after steroid alone or CsA plus steroid treatment</time_frame>
    <description>serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>FSGS</condition>
  <arm_group>
    <arm_group_label>steroid-sensitive FSGS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>steroid-dependent and resistant FSGS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1)the patients with steroid-sensitive FSGS;2)the cyclosporine A-treated patients with
        steroid-dependent and steroid-resistant FSGS;3)the healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry is between 14 and 70 years

          -  biopsy-proven primary FSGS

          -  proteinuria &gt;=3 g/day

          -  without corticosteroids or CsA treatment before entry

        Exclusion Criteria:

          -  Chronic Inflammatory Diseases

          -  malignant tumor

          -  diabetes mellitus

          -  contraindications for the treatment of corticosteroids or CsA treatment

          -  untolerate to or unwilling to accept corticosteroids or CsA treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Shi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Dept.,Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Shi, MD,PhD</last_name>
    <phone>86-20-8385-0849</phone>
    <email>weishi_gz@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nephrology Dept.,Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Shi, MD,PhD</last_name>
      <phone>86-20-8385-0849</phone>
      <email>weishi_gz@126.com</email>
    </contact>
    <investigator>
      <last_name>Bin Zhang, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruizhao Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong General Hospital</investigator_affiliation>
    <investigator_full_name>Wei Shi</investigator_full_name>
    <investigator_title>Director of renal division of Guangdong General Hospital</investigator_title>
  </responsible_party>
  <keyword>FSGS</keyword>
  <keyword>suPAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

